ISCT 2023 Session “Automation and Digitalization in Manufacturing” Highlights
Outstanding ISCT 2023 session in Paris, France “Automation and Digitalization in Manufacturing” moderated by Shannon Eaker with J. Kelly Ganjei, Edwin Stone, and Jeet Sarkar. What are the barriers to the adoption of automation and digitization in manufacturing and what are the range of explore potential solutions? Panel makes the point that the industry currently […]
Quick Facts about Blood Centers of America and its Advanced Therapies Network
Four facts about BCA’s Advanced Therapies Network BCA centers generate >$3B in revenue annually managing >50% of the country’s supply of blood and blood components from >500 facilities owned by ~65 centers in 43 states supplying biomaterials from >3.5 million annual donors to thousands of hospitals. BCA additionally represents access to 7 cord blood banks, […]
BioBridge Global Profiled 2023 Affiliate Member of AATB
BCA member, BioBridge Global, becomes an affiliate member of AATB BCA is thrilled to announce that BioBridge Global, one of our member centers, has been profiled by our sister organization AATB. BioBridge Global is a nonprofit organization that utilizes advanced therapies to improve and save patients’ lives. Blood Centers of America is proud of its […]
Legend Biotech and The Janssen Pharmaceutical Companies of Johnson & Johnson Seek Approval of Carvykti
Legend Biotech and The Janssen Pharmaceutical Companies of Johnson & Johnson seek approval to get their Carvykti CAR T-Cell multiple myeloma treatment to more patients With its latest FDA filing, Legend Biotech and The Janssen Pharmaceutical Companies of Johnson & Johnson seeks approval to get their Carvykti CART-Cell treatment to more patients. After gaining approval […]
FDA Accepts Iovance Biotherapeutics’ BLA Submission
Iovance Biotherapeutics, Inc. announces the FDA acceptance of its BLA submission In another step toward commercial approval, Iovance Biotherapeutics, Inc. announced yesterday that with the FDA acceptance of its BLA submission for its lifileucel cell therapy and its Priority Review status, its PDUFA date is November 25 of this year. Furthermore, the FDA is not […]
Relationship Between the Apheresis Center and the Cell Therapy Developer
The relationship between the apheresis center and cell therapy developer/provider An outstanding article from Suzanne Kamps of Adaptimmune in Cell & Gene Therapy Insights on the growing importance of the relationship between the apheresis center and cell therapy developer/provider. “…clearly communicating our (Adaptimmune) message about our specific treatment and allowing apheresis centers the autonomy to […]
New York Blood Center Unveils $50 Million Investment Fund
New York Blood Center Unveils NYBC Ventures Blood Centers of America member, New York Blood Center, unveils its $50 million investment fund called NYBC Ventures. This newly formed investment fund focusses on blood and cellular therapeutics. The financing for this new venture is tied to proceeds from solvent detergent plasma processes, patented by NYBC. Since […]
2023 Cell Therapy Accomplishments So Far
Cell therapies made significant improvements in Q1 2023 Thus far in 2023: One cell therapy BLA approved by the FDA (1st expanded hematopoietic stem cell product, 1st manufactured umbilical cord blood services product). Four advanced therapies BLA submissions: First Iovance (1st TIL cell therapy), Next, Adaptimmune (1st engineered TCR cell therapy), Then, 1st BLA submission […]
LifeSouth Community Blood Centers Selected to Provide Umbilical Cord Blood-Derrived CD34 Cells for ISS Mission
Blood Centers of America member, LifeSouth Community Blood Centers, selected to provide CD34 cells to Dr. Abba C. Zubair of Mayo Clinic. Blood Centers of America member LifeSouth Community Blood Centers, headquartered in Gainesville, Fla., was selected to provide umbilical cord blood-derived CD34 cells to regenerative medicine specialist Dr. Abba C. Zubair of Mayo Clinic […]
Cord Blood Connect Calls for Abstracts
Cord Blood Connect calls for abstracts to publish in STEM CELLS Translational Medicine. Whether your work focuses on preclinical studies, clinical trials, perinatal tissue banking and therapies, cord blood collection, or cord blood bank management, your work is impactful to the cord blood community. Submit your abstract for consideration by June 16, 2023. Learn more […]